Study of Herbal Formula Corresponding to Syndrome in Treating Post Percutaneous Coronary Intervention (PCI) Patients With Coronary Heart Disease (CHD)

Guang'anmen Hospital of China Academy of Chinese Medical Sciences90 enrolled

Overview

We conduct this clinical trial to determine the effects of Xuefu Zhuyu capsule (based on TCM "Zheng Hou" theory) in helping recovery from coronary heart disease(CHD)after PCI and find out whether this kind of effecacy is much better within patients administered with TCM syndrome-based individualized medication.

The effectiveness of a Chinese herbal formulae is not completely based on the disease or some biomedical indexes, but much more on the TCM syndrome(Chinese name:Zheng Hou)which is generalized from patients' TCM signs and symptoms. Thus, conventional medical curative effecacy evaluation system seems not to so fit for TCM clinical studies. Although many clinical studies from Chinese literature have reported the beneficial effects of various of TCM herbal agents in improving symptoms and signs as well as antagonism of specific pathological changes in CHD patients, most of these trials are lack of well-designed methodologies and the reliability of results still remains unclear. Therefore, we designed this clinical trial, with a randomized, placebo controlled way, to evaluate the curative effects of Xuefu Zhuyu capsule(a Chinese herbal medicine)in patients with Post-PCI CHD patients and find out whether this effects will be better displayed within subjects administered with syndrome-based individualized medication.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Coronary Heart Disease

Interventions

Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules,DRUG

3# XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks

Sheng Mai Capsules Plus Placebo of Xuefu Zhuyu CapsulesDRUG

3# SM capsules plus 3# placebo of XFZY capsules, po, Tid, for 4 weeks

Placebo of Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai CapsulesDRUG

3# Placebo of XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18-75 years old * Clinical diagnosis of coronary heart disease (confirmed by coronary angiography) * Successfully received interventional therapy (PTCA or PCI) * belong to TCM blood-stasis syndrome * Must be able to swallow tablets * Able to give written informed consent Exclusion Criteria: * Symptomatic congestive heart failure(New York Heart Association class III-IV) * Females during pregnancy or lactation * Serious dysfunction in important organs (liver, lung, kidney，et al) * Use of concomitant Chinese herbal medicine * Already attend other clinical trial

Locations (1)

Guang'an Men Hospital

Beijing, China

Outcomes

Primary Outcomes

Severity of anginal attacks, alternations of TCM symptoms and signs, and electrocardiographic changes.

Time frame: 4 weeks

Secondary Outcomes

Health related quality of life (Hr-QoL); Changes in serum lipid, inflammatory reaction level and endothelial function status alternations before and after the treatment.

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.